TABLE 2.
Meta‐analysis of randomised control trials of hypertensive disorders of pregnancy
| Reference | Number of RCT | Sample IG/CG | Main outcome | Number of cases IG/CG | Type of measure (RR or OR) | RR/OR and 95% CI and of the largest study | RR/OR and 95% CI | I 2 (%) |
|---|---|---|---|---|---|---|---|---|
| Davenport et al. 21 | 23 | 2627/2689 | GH | 61/105 | OR | 1 (0.46–2.19) | 0.61 (0.43–0.85) | 0 |
| Magro‐Malosso et al. 57 | 16 | 2452/2189 | GH | 61/100 | RR | NR | 0.54 (0.40–0.74) | 10 |
| Xing et al. 61 | 5 | 428/424 | GH | NR | RR | 0.74 (0.35–1.55) | 0.53 (0.32–0.88)] | 3.7 |
| Davenport et al. 21 | 16 | 1719/1603 | PE | 34/49 | OR | 0.80 (0.27–2.40) | 0.59 (0.37–0.94) | 0 |
| Da Silva et al. 93 | 4 | 709/708 | PE | NR | RR | 0.99 (0.50, 1.96) | 0.93 (0.55–1.57) | 0 |
| Kramer et al. 64 | 1 | 43/39 | PE | 7/6/ | RR | 1.17 (0.44–3.08) | 1.17 (0.44–3.08) | NR |
| Magro‐Malosso et al., 57 | 6 | 1164/1066 | PE | 26/30 | RR | NR | 0.79 (0.45–1.38) | 0 |
| Xing et al. 61 | 5 | 499/505 | PE | NR | RR | NR | 1.00 (0.66–1.52) | 0 |
| Muhammad et al. 54 | 5 | 324/326 | GH and PE | 23/30 | RR | 0.75 (0.36–1.55) | 0.77 (0.46–1.30) | 0 |
| Rogozinska et al. 26 | 20 | 2513/2359 | HDP | 106/147 | OR | Not reported | 0.68 (0.49–0.93) | 0 |
Abbreviations: CG, control group; GH, gestational hypertension; HDP, hypertensive disorders of pregnancy; IG, intervention group; OR, odds ratio; PH, pre‐eclampsia; RCT, randomised controlled trial; RR, relative risk.